title: Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
abstract: Abstract Purine analogs are highly effective in hairy cell leukemia (HCL) with response rates of 85%, but with many late relapses. We have retrospectively reviewed the clinical data from 107 patients treated with pentostatin (n = 27) or cladribine (n = 80), to investigate the long-term efficacy and to identify factors associated with the treatment-free interval (TFI). Complete remission and minimal residual disease (MRD) rates were similar in both groups. Median TFI was shorter (95 vs. 144 months) in the pentostatin group, although the difference was not significant (p = 0.476). MRD+ patients had shorter TFI than MRD- patients (97 months vs. not reached, p < 0.049). A hemoglobin level < 10 g/dL predicted for a shorter TFI only in the pentostatin group. Quality of response and number of hairy cells in the bone marrow are independent risk factors of treatment failure. The relationship between MRD+ and shorter TFI makes it of special interest to explore consolidation therapy with monoclonal antibodies to achieve durable responses.
authors.affiliation: Hospital U. Príncipe de Asturias, Alcalá de Henares , Madrid , Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: López Rubio
authors.forename: Carolina
authors.initials: C
authors.lastname: Da Silva
authors.forename: Javier
authors.initials: J
authors.lastname: Loscertales
authors.forename: Cristina
authors.initials: C
authors.lastname: Seri
authors.forename: Patricia
authors.initials: P
authors.lastname: Baltasar
authors.forename: Enrique
authors.initials: E
authors.lastname: Colado
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Pérez Fernández
authors.forename: Mar
authors.initials: M
authors.lastname: Osma
authors.forename: Federico
authors.initials: F
authors.lastname: Gomis
authors.forename: Marcos
authors.initials: M
authors.lastname: González
authors.forename: Isidro
authors.initials: I
authors.lastname: Jarque
authors.forename: Manuel
authors.initials: M
authors.lastname: Vargas
authors.forename: Encarnación
authors.initials: E
authors.lastname: Monzó
authors.forename: Dolores
authors.initials: D
authors.lastname: Monteagudo
authors.forename: Maria Isabel
authors.initials: MI
authors.lastname: Orts
authors.forename: Emilia
authors.initials: E
authors.lastname: Pardal
authors.forename: Félix
authors.initials: F
authors.lastname: Carbonell
authors.forename: Cesar
authors.initials: C
authors.lastname: Perez Calvo
authors.forename: Jose A
authors.initials: JA
authors.lastname: Garcia-Marco
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017338:Cladribine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015649:Pentostatin / Q000008:administration & dosage / Q000627:therapeutic use*; D000069283:Rituximab; D013156:Splenectomy; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D016898:Interferon-alpha; D015649:Pentostatin; D017338:Cladribine; D000069283:Rituximab